Based on the most recent data from Jul 31, 2026, AZN's PEG ratio comes in at 0.97. This metric factors in a PE of 25.17 with an earnings growth rate of 26.0%. Relative to the 0.78 average from the previous four quarters, the PEG ratio has grown by 24%.
Looking at the last ten years, AZN's PEG ratio has has been around 1.17 on average. At 0.97, today's PE to growth ratio sits 17% below its historical average. Within the last ten years, the Jun 2024 quarter recorded the highest PEG value at 7.81. At 0.03, the Dec 2022 quarter showed the minimum PEG ratio in this period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.61 | 27.86 | 45.4% |
| 2024 | 1.59 | 28.86 | 18.2% |
| 2023 | 0.43 | 35.08 | 81.1% |
| 2022 | 0.03 | 63.96 | 2,550% |
| 2021 | N/A | 1,456.25 | -96.7% |
| 2020 | 0.3 | 40.98 | 136.9% |
| 2019 | N/A | 96.82 | -39.4% |
| 2018 | N/A | 44.68 | -28.3% |
| 2017 | N/A | 29.28 | -14.4% |
| 2016 | 0.82 | 19.73 | 24.2% |
| 2015 | 0.24 | 30.45 | 127.6% |
| 2014 | N/A | 71.82 | -52% |
| 2013 | N/A | 29.1 | -58.8% |
| 2012 | N/A | 9.55 | -32.1% |
| 2011 | 0.21 | 6.35 | 30.2% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 1.08 | 28.13 | 26% |
| Mar 2026 | 0.87 | 29.39 | 33.9% |
| Dec 2025 | 0.61 | 27.86 | 45.4% |
| Sep 2025 | 0.56 | 25.28 | 44.9% |
| Jun 2025 | 0.91 | 26.12 | 28.6% |
| Mar 2025 | 1.3 | 29.34 | 22.5% |
| Dec 2024 | 1.59 | 28.86 | 18.2% |
| Sep 2024 | 3.61 | 37.19 | 10.3% |
| Jun 2024 | 7.81 | 37.5 | 4.8% |
| Mar 2024 | 0.95 | 33.13 | 35% |
| Dec 2023 | 0.43 | 35.08 | 81.1% |
| Sep 2023 | 0.15 | 35.64 | 242.3% |
| Jun 2023 | 0.08 | 36.06 | 478.1% |
| Mar 2023 | 0.1 | 45.82 | 452.3% |
| Dec 2022 | 0.03 | 63.96 | 2,550% |
AZN's PEG ratio today is below the 3, 5 and 10-year averages.
Astrazeneca's PEG of 0.97 is above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 0.56, Astrazeneca's PEG is 73% higher.
AZN has a PEG ratio above that of peer stocks LLY and BMY.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| BMY Bristol-Myers Squibb Company | 0.17 | $131.84B |
| LLY Lilly(Eli) & Company | 0.31 | $1.06T |
| AZN Astrazeneca plc | 0.89 | $241.13B |
| PFE Pfizer Inc | N/A | $142.37B |
| MRK Merck & Co Inc | N/A | $316.38B |
| JNJ Johnson & Johnson | N/A | $607.73B |
| BIIB Biogen Inc | N/A | $29.95B |
| ABT Abbott Laboratories | N/A | $185.72B |
| NVS Novartis AG | N/A | $293.47B |
AZN shows a PEG ratio of 0.97, per Jul 31, 2026 data.
AZN's 3-year PEG ratio average stands at 1.66.
AZN's 5-year PEG ratio average stands at 1.34.
The Jun 2024 quarter marked the ten years high at 7.81 for AZN's PEG ratio.
AZN currently has a PEG ratio 17% below its 10-year average.
Computing the PEG ratio involves dividing the PE ratio by the company's EPS growth (YoY TTM). As of Jul 31, 2026, Astrazeneca has a P/E ratio of 25.17. Earnings grew at 26.0% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 0.97. PEG RATIO(0.97) = PE RATIO(25.17) / EPS GROWTH(26.0%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.